pharmaphorum June 13, 2024
Pfizer has had some setbacks in its efforts to develop drugs for the lucrative obesity market, but could see its pipeline swell thanks to its $7 billion partnership with venture capital firm Flagship Pioneering.
Flagship has just announced that it will work with biotech start-up ProFound Therapeutics to find first-in-class protein therapeutics with potential in obesity, confirming this is the first programme in the alliance with Pfizer signed last July.
The announcement comes just a few months after Pfizer was forced to abandon two of its obesity candidates. Most recently, it shelved a twice-daily formulation of oral GLP-1 receptor agonist danuglipron after seeing a high dropout rate in a mid-stage clinical trial due to side effects, having previously stopped work...
Today's Sponsors
Today's Sponsor